# Intralymphatic Immunotherapy in Increasing Doses, After Subcutaneous Immunotherapy

> **NCT02679105** · PHASE2,PHASE3 · COMPLETED · sponsor: **Karolinska Institutet** · enrollment: 38 (actual)

## Conditions studied

- Rhinitis, Allergic

## Interventions

- **DRUG:** ALK Alutard birch or 5-grasses
- **DRUG:** ALK diluent

## Key facts

- **NCT ID:** NCT02679105
- **Lead sponsor:** Karolinska Institutet
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05
- **Primary completion:** 2016-10
- **Final completion:** 2019-03
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2019-09-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02679105

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02679105, "Intralymphatic Immunotherapy in Increasing Doses, After Subcutaneous Immunotherapy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02679105. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*